Paper37535237
The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Bendotti G and 5 others. J Endocrinol Invest, 2023. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. Papers, record 37535237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37535237
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sodium-Glucose Transporter 2 Inhibitors | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Humans | |
| Hypoglycemic Agents | |
| Anti-Inflammatory Agents | |
| Glucose |
Source PubMed
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36134918 | Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. | Diabetes Care | 2022 | https://conductscience.org/library/papers/36134918 | PubMed |
| 2 | 33728820 | Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. | FEBS Open Bio | 2021 | https://conductscience.org/library/papers/33728820 | PubMed |
| 3 | 33160017 | The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion. | Cell Signal | 2021 | https://conductscience.org/library/papers/33160017 | PubMed |
| 4 | 21838680 | The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. | Curr Diabetes Rev | 2011 | https://conductscience.org/library/papers/21838680 | PubMed |
| 5 | 31011203 | A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. | Nat Med | 2019 | https://conductscience.org/library/papers/31011203 | PubMed |
| 6 | 31477497 | SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. | Cell Metab | 2019 | https://conductscience.org/library/papers/31477497 | PubMed |
| 7 | 3906359 | Protein glycosylation and the pathogenesis of atherosclerosis. | Metabolism | 1985 | https://conductscience.org/library/papers/3906359 | PubMed |
| 8 | 29573529 | Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/29573529 | PubMed |
| 9 | 8596407 | Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. | Lancet | 1996 | https://conductscience.org/library/papers/8596407 | PubMed |
| 10 | 35620570 | Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes. | J Diabetes Res | 2022 | https://conductscience.org/library/papers/35620570 | PubMed |
| 11 | 20447870 | Immunological and regenerative properties of cord blood stem cells. | Clin Immunol | 2010 | https://conductscience.org/library/papers/20447870 | PubMed |
| 12 | 16290958 | Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. | Am Heart J | 2005 | https://conductscience.org/library/papers/16290958 | PubMed |
| 13 | 31001673 | Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. | Diabetologia | 2019 | https://conductscience.org/library/papers/31001673 | PubMed |
| 14 | 29923295 | Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/29923295 | PubMed |
| 15 | 35712355 | Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/35712355 | PubMed |
| 16 | 16168295 | Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study. | J Am Coll Cardiol | 2005 | https://conductscience.org/library/papers/16168295 | PubMed |
| 17 | 28104929 | The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice. | Mediators Inflamm | 2016 | https://conductscience.org/library/papers/28104929 | PubMed |
| 18 | 33771372 | Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. | Hum Immunol | 2021 | https://conductscience.org/library/papers/33771372 | PubMed |
| 19 | 35126822 | Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice. | Oxid Med Cell Longev | 2022 | https://conductscience.org/library/papers/35126822 | PubMed |
| 20 | 32726607 | SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. | Cell Metab | 2020 | https://conductscience.org/library/papers/32726607 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42959627 | Decoding inflammation to target hybrid diabetes phenotypes. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42959627 | PubMed |
| 42681829 | Initiation of SGLT2 Inhibitors Versus DPP-4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims-Based Active-Comparator New-User Study. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42681829 | PubMed |
| 42591999 | Mitochondrial-inflammatory coupling in HFpEF: an emerging mechanistic framework for understanding the cardioprotective effects of SGLT2 inhibitors. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42591999 | PubMed |
| 42233563 | SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. | JACC Asia | 2026 | https://conductscience.org/library/papers/42233563 | PubMed |
| 41771397 | Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study. | J Card Fail | 2026 | https://conductscience.org/library/papers/41771397 | PubMed |
| 41752654 | Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/41752654 | PubMed |
| 41619161 | Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/41619161 | PubMed |
| 41505051 | Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/41505051 | PubMed |
| 41489806 | Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail? | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/41489806 | PubMed |
| 41469686 | Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation. | BMC Med | 2025 | https://conductscience.org/library/papers/41469686 | PubMed |
| 41126323 | The association between glycated hemoglobin and intraocular inflammatory factors in patients with proliferative diabetic retinopathy. | Int J Retina Vitreous | 2025 | https://conductscience.org/library/papers/41126323 | PubMed |
| 41093607 | Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study. | BMJ | 2025 | https://conductscience.org/library/papers/41093607 | PubMed |
| 40978121 | Sodium-glucose co-transporter-2 inhibitors vs metformin in reducing osteoarthritis risk: a retrospective cohort study of health insurance claims and check-up data. | JBMR Plus | 2025 | https://conductscience.org/library/papers/40978121 | PubMed |
| 40696035 | Relationship between aggregate index of systemic inflammation and mortality from CCD and malignant neoplasms in diabetic patients. | Sci Rep | 2025 | https://conductscience.org/library/papers/40696035 | PubMed |
| 40665981 | Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40665981 | PubMed |
| 40620843 | Impact of Albuminuria and Renal Dysfunction on the Anemia-Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real-World Observational Study. | J Diabetes Res | 2025 | https://conductscience.org/library/papers/40620843 | PubMed |
| 40420176 | Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. | Cardiovasc Diabetol | 2025 | https://conductscience.org/library/papers/40420176 | PubMed |
| 40193211 | Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies. | J Am Soc Nephrol | 2025 | https://conductscience.org/library/papers/40193211 | PubMed |
| 40127201 | Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study. | Rheumatology (Oxford) | 2025 | https://conductscience.org/library/papers/40127201 | PubMed |
| 40123308 | Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes. | J Diabetes Investig | 2025 | https://conductscience.org/library/papers/40123308 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37535237
GET https://conductscience.org/api/papers/v1/37535237/references?page=2